Lexeo Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Lexeo Therapeutics highlights advancements in its gene therapy pipeline targeting cardiovascular and neurodegenerative diseases, including positive clinical data updates and regulatory alignment for its lead candidates.
NASDAQ
10-K: Lexeo Therapeutics Details Capital Stock Structure and Anti-Takeover Provisions in 10-K Filing
Lexeo Therapeutics outlines its capital stock structure, including common and preferred stock details, voting rights, dividend policies, and anti-takeover provisions in its recent 10-K filing.